The presence of 5-hydroxymethylcytosine (hmC) in the nuclei of Purkinje neurons and the brain was identified by Skirmantas Kriaucionis and Nathaniel Heintz. Using techniques such as thin layer chromatography (TLC), high pressure liquid chromatography (HPLC), and mass spectrometry (MS), they detected hmC in Purkinje cells at 0.6% and in granule cells at 0.2% of total nucleotides, but not in cancer cell lines. This suggests a potential role in epigenetic regulation of neuronal function. To isolate Purkinje and granule cell nuclei, the researchers used transgenic mice expressing fluorescent ribosomal proteins. They found that hmC is enriched in the brain, particularly in the cortex and brainstem, but not in other metabolically active non-proliferating tissues. They also observed that hmC is not a product of DNA damage, as no other DNA damage products were detected. The presence of hmC in mouse cerebellar DNA was confirmed through mass spectrometry, which identified ions matching those of hmC. The researchers noted that hmC is nearly 40% as abundant as 5-methylcytosine (mC) in Purkinje cell DNA. They suggest that hmC may serve as an intermediate or stable end-product in oxidative demethylation, modulating protein affinity for mC signals in non-dividing neurons. The study also notes that earlier reports of hmC in mammalian genomes have not been reproduced. However, the presence of hmC in the brain, but not in other tissues, and its lack of correlation with age, suggests a specific biological role. The findings highlight the potential importance of hmC in epigenetic regulation, particularly in the brain. The study was supported by the Howard Hughes Medical Institute and the Simons Foundation Autism Research Initiative.The presence of 5-hydroxymethylcytosine (hmC) in the nuclei of Purkinje neurons and the brain was identified by Skirmantas Kriaucionis and Nathaniel Heintz. Using techniques such as thin layer chromatography (TLC), high pressure liquid chromatography (HPLC), and mass spectrometry (MS), they detected hmC in Purkinje cells at 0.6% and in granule cells at 0.2% of total nucleotides, but not in cancer cell lines. This suggests a potential role in epigenetic regulation of neuronal function. To isolate Purkinje and granule cell nuclei, the researchers used transgenic mice expressing fluorescent ribosomal proteins. They found that hmC is enriched in the brain, particularly in the cortex and brainstem, but not in other metabolically active non-proliferating tissues. They also observed that hmC is not a product of DNA damage, as no other DNA damage products were detected. The presence of hmC in mouse cerebellar DNA was confirmed through mass spectrometry, which identified ions matching those of hmC. The researchers noted that hmC is nearly 40% as abundant as 5-methylcytosine (mC) in Purkinje cell DNA. They suggest that hmC may serve as an intermediate or stable end-product in oxidative demethylation, modulating protein affinity for mC signals in non-dividing neurons. The study also notes that earlier reports of hmC in mammalian genomes have not been reproduced. However, the presence of hmC in the brain, but not in other tissues, and its lack of correlation with age, suggests a specific biological role. The findings highlight the potential importance of hmC in epigenetic regulation, particularly in the brain. The study was supported by the Howard Hughes Medical Institute and the Simons Foundation Autism Research Initiative.